R E L A P S E D / R E F R A C T O R Y

Full text

(1)

Thursday, 11 June 2015

08.00–10.00

Room C1

Reed Messe Vienna

Messeplatz 1

1020 Vienna, Austria

This activity is provided by prIME Oncology.

Sa

te

llit

e S

ym

pos

ium

at t

he 20

th

Congress of the European H

emato

logy

Ass

ocia

tio

n

RE

LA

P S E

D / R E F R A CT

OR

Y

M

U L

T I P

L E M Y E L O

MA

:

EM

BR

AC

ING

THE

PERSON IN PERSONA

LIZE

D C

AR

E

(2)

RELAPSED/REFRACTORY

EMBRACING THE PERSON IN PERSONALIZED CARE

Satellite Symposium at the 20th Congress of the European Hematology Association

CHAIR

Antonio Palumbo, MD

University of Torino Torino, Italy

FACULTY

Meletios Dimopoulos, MD

University of Athens Athens, Greece

Paul Richardson, MD

Dana-Farber Cancer Institute Boston, Massachusetts, United States

Jesús San Miguel, MD, PhD

Universidad de Navarra Navarra, Spain

PATIENT WITH MM

Mr. Yelak Biru

Dallas, Texas, United States

WELCOME LETTER

Dear Colleagues,

Welcome to Vienna and the 20th Congress of the European Hematology Association.

We are very pleased that you have chosen to attend this prIME Oncology satellite symposium, Relapsed/Refractory Multiple Myeloma: Embracing the Person in Personalized Care.

With this educational activity, we hope to provide you with the most up-to-date and relevant information about treatment advances in multiple myeloma. We hope you will find our symposium informative and engaging.

We appreciate your attendance and welcome your active participation.

Antonio Palumbo, MD University of Torino Torino, Italy Thursday, 11 June 2015 08.00–10.00 Room C1

Reed Messe Vienna

AGENDA

Welcome and introduction

Antonio Palumbo, MD

08.00 Keynote lecture–Tailoring therapy in relapsed/refractory multiple myeloma (MM): Balancing the science with the individual Antonio Palumbo, MD

08.15 Moving forward with immunomodulatory agents in MM

Meletios Dimopoulos, MD 08.30 Patient experience with

immunomodulatory agents Yelak Biru

08.40 Q & A

08.45 Progress in proteasome inhibition: Today and tomorrow

Jesús San Miguel, MD, PhD 09.00 Patient experience with

proteasome inhibitors Yelak Biru

09.10 Q & A

09.15 What lies ahead? Future therapeutic strategies Paul Richardson, MD

09.35 Patient experience addressing what lies ahead Yelak Biru

09.45 Q & A

09.50 Taking next steps: A panel discussion 10.00 Key pointsand adjourn

(3)

ACTIVITY OVERVIEW

ACTIVITY OVERVIEW

TARGET AUDIENCE

This educational activity is designed for hematologists, oncologists, and other healthcare professionals interested and/or involved in the treatment of patients with relapsed/refractory MM.

LEARNING OBJECTIVES

After successful completion of this educational activity, participants should be able to: • Discuss patient perspectives on evolving therapeutic strategies for relapsed/refractory

MM, including the impact of mode of drug administration and treatment-related adverse events on quality of life

• Employ best practices in the treatment of patients with relapsed/refractory MM, including optimal use of available agents, such as immunomodulatory drugs and proteasome inhibitors

• Evaluate recent clinical trial data and ongoing studies focused on the efficacy and safety of novel therapies for the treatment of relapsed/refractory MM

• Describe how emerging therapeutic options may fit into the current treatment landscape for relapsed/refractory MM

• Identify strategies to balance quality of life and efficacy when making treatment decisions for patients with relapsed/refractory MM

CONTINUING EDUCATION

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.

prIME Oncology designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

DISCLOSURE

Disclosure of Relevant Financial Relationships

prIME Oncology assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Mr Biru has disclosed that he has no relevant financial relationships to disclose. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Dimopoulos has disclosed that he has received honoraria/consulting fees from Celgene, Janssen, Novartis, and Onyx. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Palumbo has disclosed that he has performed as a consultant or advisor for Amgen, Bristol-Myers Squibb, Genmab A/S, Celgene, Janssen-Cilag, Millennium Pharmaceuticals, Inc., and Onyx Pharmaceuticals. Furthermore, he disclosed receipt of honoraria from Amgen, Bristol-Myers Squibb, Genmab A/S, Celgene, Janssen-Cilag, Millennium Pharmaceuticals, Novartis, Onyx Pharmaceuticals, and Sanofi Aventis. He has agreed to disclose any unlabeled/ unapproved uses of drugs or products referenced in his presentation.

Dr Richardson has disclosed that he was a member of the Advisory Committees of Bristol Myers Squibb, Celgene, Genmab, Johnson & Johnson, Millennium, Novartis, and Onyx. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr San Miguel has disclosed that he has been on the advisory board for Bristol-Myers Squibb, Celgene, Janssen, Millennium, MSD, Novartis, and Onyx. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

The employees of prIME Oncology have disclosed:

• Janice Galleshaw, MD (medical director content reviewer/planner) – no relevant financial relationships • Sanneke Koekkoek, RN (clinical content reviewer/planner) – no relevant financial relationships • Christi Gray (editorial content reviewer) – no relevant financial relationships

PROVIDER

SUPPORT

This activity is provided by prIME Oncology.

(4)

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

ACTIVITY OVERVIEW

CHAIR BIOGRAPHY

Antonio Palumbo, MD

Antonio Palumbo, MD, received his medical degree, served his residency in internal medicine, and held a fellowship in hematology/oncology at the University of Torino in Italy. Before his current position as chief of the Myeloma Unit of the Department of Oncology, Section of Hematology, University of Torino, he was a research associate at the Wistar Institute, University of Pennsylvania in the United States.

Dr Palumbo specializes in malignant hematology and medical oncology and has clinical and research interest in plasma cell dyscrasia.

In addition to membership in numerous professional organizations, he has authored more than 100 publications in peer-reviewed journals, as well numerous abstracts and several textbooks chapters. His current research focuses on the pathogenesis and treatment of multiple myeloma.

(5)

FACULTY BIOGRAPHY

FACULTY BIOGRAPHY

Meletios Dimopoulos, MD

Meletios Dimopoulos, MD, is professor and chairman of the Department of Clinical Therapeutics at the National and Kapodistrian University of Athens School of Medicine, Athens, Greece. He was elected vice dean of the medical school from 2007 to 2011, and he became dean in 2011-2015. In February 2015, he was elected Rector of the National and Kapodistrian University of Athens for a 4 year term.

He obtained his medical degree from the University of Athens in 1985, completed a residency in internal medicine at the Royal Victoria Hospital, McGill University in Montreal, Canada, and completed a fellowship in hematology/oncology at the University of Texas M.D. Anderson Cancer Center in Houston, Texas, United States.

Dr Dimopoulos is a member of numerous scientific societies, and has authored more than 700 publications in peer-reviewed journals, as well as numerous abstracts and several textbook chapters primarily focusing on plasma cell dyscrasias and genitourinary and gynecologic cancers. He has more than 24,000 citations and his H-index is 75. He is a journal reviewer for several journals, including New England Journal of Medicine, Blood, Journal of Clinical Oncology, Haematologica, Leukemia, Cancer, European Journal of Haematology, Leukemia, and Lymphoma. He was associate editor of the European Journal of Internal Medicine (2001-2007), is an associate editor of Current Hematologic Malignancy Reports, and was an editorial board member of the Journal of Clinical Oncology (2005-2008). He is currently on the editorial board of Haematologica, Leukemia and Lymphoma, Clinical Lymphoma and Myeloma, and Expert Review of Hematology.

Mr. Yelak Biru

Diagnosed at a young age of 25 with stage III myeloma, Yelak Biru is a patient turned myeloma research advocate. Working with a team of medical practitioners and educating himself through active support group leadership, online information, advocacy sites, social media, and the IMF, Yelak has been able to successfully integrate myeloma to his life for almost two decades.

From the time he was told he has, give or take, three years to live in 1996, Yelak has learned to balance life based on the realization that life is both brittle and finite, and he has come to realize the uncertainty of myeloma treatment and its outcomes keeping hope based on the reality of continuing time and the possibilities of tomorrow. Sharing that hope is his personal motivation and the motto of the North Texas Myeloma Support Group, one of the oldest myeloma support groups in North America of which he leads.

Yelak has attended a half dozen American Hematology Association conferences, myeloma satellite symposiums, International Myeloma Working Group breakfasts, debates, and regional and community myeloma workshops, where he has been able to hear from leading myeloma researchers and practitioners.

Yelak believes through research advocacy patients will be able to better balance quality of life with treatment outcomes while helping to accelerate both translational and basic myeloma research.

Mr Biru has been treated with the “old dog” treatment regimen of VAD (vincristine-doxorubicin-dexamethasone) as well as with novel immunomodulatory drugs and proteasome inhibitors both as induction and maintenance, and he has so far avoided stem cell transplant.

(6)

FACULTY BIOGRAPHY

Paul Richardson, MD

Paul Richardson, MD, earned his medical degree at the Medical College of St Bartholomew’s Hospital, University of London, in the United Kingdom. His postdoctoral training included an internship in the Departments of Medicine and Surgery at St Bartholomew’s Hospital; residency in the Department of Medicine at Newcastle University School of Medicine, Newcastle General and Freeman Hospitals in Newcastle-upon-Tyne; chief residency in medical oncology at the Royal Marsden Hospital in London and Surrey; and additional residency training at the Beth Israel Hospital in Boston, Massachusetts, United States. He completed fellowships in hematology/oncology and medical oncology at Tufts University School of Medicine, Baystate Medical Center, and Harvard Medical School, Dana-Farber Cancer Institute, all in Massachusetts.

Board certified in internal medicine, medical oncology, and hematology, Dr Richardson holds leadership positions in several professional bodies and serves on the editorial board for a number of journals, including the British Journal of Haematology, The Oncologist, and Clinical Cancer Research. He is past-chair of the Multiple Myeloma Research Consortium, Clinical Trials Core, and served on the American Society of Clinical Oncology ACRA Hematologic Malignancies Subcommittee. He is currently chairman of the Myeloma Committee for the Alliance (the former CALGB). His honors include several Massachusetts General Hospital, Brigham and Women’s Hospital, and Dana-Farber Partners in Excellence Awards; the Brigham and Women’s Hospital Teaching Scholars Award; the Dana-Farber Cancer Institute’s George Canellos Award for Excellence in Clinical Research and Patient Care; the Tisch Family Outstanding Achievement Award, and the Warren Alpert Foundation Prize.

Dr Richardson has published more than 280 original articles, and more than 220 reviews, chapters, and editorials in top peer-reviewed journals including the New England Journal of Medicine, Blood, Journal of Clinical Oncology, Lancet Oncology, Leukemia, Clinical Cancer Research, Hematologica, and British Journal of Haematology.

Dr Richardson is a highly sought invited lecturer both nationally and internationally. Currently, he is leading multiple efforts studying the use of combination therapies in relapsed and refractory myeloma, an area of primary interest to him. He is also serving as a principal investigator and study chairman for several large multicenter clinical trials relating to other areas of myeloma treatment, including the use of combination therapies as initial treatment and timing of stem cell transplant in earlier disease designed to target resistance and reduce toxicity.

FACULTY BIOGRAPHY

Jesús San Miguel, MD, PhD

Jesús San-Miguel, MD, PhD, is a professor of medicine-hematology and director of clinical and translational medicine at the University of Navarra in Spain. He served as director of the Hematology Department of the University Hospital of Salamanca in Spain, for over 22 years (1991-2013).

Dr San-Miguel has published over 700 original papers in international journals with a median impact factor of 7.6 in the last five years. His areas of interest include multiple myeloma (MM), the biology of malignant cells and their prognostic implications, and minimal residual disease.

He has made important contributions to myeloma cell biology in areas such as immunephenotyping, risk of progression from monoclonal gammopathy of undetermined significance or smouldering MM into active MM, and minimal residual disease, as well as, making important contributions in the area of therapeutics, including studies for new antimyeloma drugs at the preclinical and clinical levels, including proteasome inhibitors, immunemodulatory drugs, and histone deacetylases.

He is a member of the Advisory Board of the International Myeloma Foundation and the Multiple Myeloma Research Foundation. He has served as board councillor for the European Association, chairman of the Scientific Committee for the IXth Congress (2004), and president of the 15th European Hematology Association (EHA) Congress. He is associate editor for Blood. He has received numerous awards, including the Waldenstöm Award, Kyle Lifetime Achievement Award, Jose Carreras EHA Award, Ham-Wasserman Lecture Award, Rey Jaime I Award in Clinical Medicine, and the Spanish Prizes in both oncology and translational research.

(7)

IDEAS, FACTS, OR CONCEPTS TO REMEMBER

QUESTIONS

I CAN USE THIS IN MY PRACTICE

(8)

IDEAS, FACTS, OR CONCEPTS TO REMEMBER

QUESTIONS

I CAN USE THIS IN MY PRACTICE

(9)

Webcast and downloadable slide will be availabe in July at

www.prIMEoncology.org/MM_Vienna2015_Webcast

(10)

EU Office prIME Oncology Schenkkade 50, Suite 16 2595 AR The Hague the Netherlands tel + 31.70.3067.190

About prIME Oncology

prIME Oncology is a global professional Independent Medical Education organization specializing in educational activities for physicians who treat patients with cancer. With the ultimate goal of improving patient outcomes, prIME Oncology provides evidence-based, state-of-the-art educational activities that assist oncology clinicians in making up-to-date and appropriate treatment decisions.

www.prIMEoncology.org

US Office prIME Oncology

Two Concourse Pkwy, Suite 260 Atlanta, Georgia 30328 United States tel + 1.678.892.1340

Figure

Updating...

References

Updating...

Related subjects :